Pulmonary Arterial Hypertension
Preclinical models for vascular remodeling and right heart dysfunction
Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary disease marked by elevated pulmonary pressure and right ventricular remodeling. CorDynamics offers validated rodent models—Monocrotaline and Hypoxia + Sugen—to support the discovery of therapies targeting pulmonary vascular pathology.
Preclinical Models of PAH
PAH models are designed to replicate the key clinical features of the disease, including pulmonary vascular remodeling, increased right heart pressure, and reduced oxygenation capacity. CorDynamics supports both preventive and interventional study designs using two gold-standard rodent models:
Monocrotaline (MCT) Model:
- Chemically induced model used for short- to mid-term studies
- Right ventricular hypertrophy and pulmonary edema observed within 3 weeks
- Vessel wall thickening correlates with elevated pulmonary arterial pressure
- Commonly used to screen dose levels and candidate compounds
Hypoxia + Sugen (SuHx) Model:
- Robust, VEGF-inhibited model with strong pathologic similarity to human PAH
- Pulmonary arteriolar occlusion and endothelial overgrowth
- Right heart dysfunction measured by echocardiography and catheterization
- Extensively validated with multiple positive controls (e.g., PDE5, ET-1, sGC, sotatercept)
- Ideal for long-term interventional therapy studies (4–9+ weeks)
Importantly, these models enable:
- Assessment of anti-proliferative, anti-fibrotic, and vasodilatory therapies
- Mechanistic studies of vascular remodeling and right heart function
- Dose optimization and biomarker validation
- Translational support for IND-enabling and early clinical studies
Why Choose CorDynamics
CorDynamics has conducted PAH studies for more than 200 clients over the past two decades, with deep expertise in model design, execution, and interpretation.
We offer dedicated hypoxia chambers for high-throughput SuHx studies and full integration of catheter-based pressure analysis and right heart echocardiography—delivering high-quality, reproducible data that supports confident go/no-go decisions.
Supporting confident decisions in PAH drug development through robust, translational data.
